QUT partners with Eclipse Ingredients in a $5.5M project to commercialise human lactoferrin protein
QUT researchers are helping to change the face of functional food and beverage ingredients, sports nutrition and skin care through a research project that will commercialise human lactoferrin, a powerful protein that provides immune support.
First published 15 July 2025
The $5.5 million project to reproduce human lactoferrin with yeast has been made possible through co-investment from Australia’s Food and Beverage Accelerator (FaBA), along with its research partners QUT, The University of Queensland and CSIRO.
QUT Chief Investigator Dr James Behrendorff, from the School of Biology and Environmental Science, said that QUT’s ability to demonstrate scalable manufacturing was an important piece of the puzzle, enabling researchers to test the yeast-made lactoferrin from micro-scale through to 2000L production capability.
"We're extremely excited to partner with Eclipse on this project that will develop precision fermentation for high-value ingredients from the lab bench all the way to pilot-scale manufacturing,” Dr Behrendorff said.
Eclipse Ingredients CEO Siobhan Coster said lactoferrin was a protein found throughout the body, from breastmilk to immune cells, and was known for its numerous health benefits, including immune and microbiome support, boosting iron levels and fighting disease and bacteria.
“Lactoferrin has incredible qualities that are hugely beneficial for our health, yet the human version has been impossible to produce at scale” Ms Coster said.
“This partnership gives us access to world-class facilities and expertise, allowing us to focus on what we do best - turning breakthrough science into products that change lives.”
Professor Jolieke van der Pols
Eclipse Ingredients initially plans to develop products for skin care before moving into functional food and beverage ingredients and infant formula before the end of the decade.
FaBA Director Dr Chris Downs said the multi-institutional Eclipse project positions Queensland as a global hub for precision fermentation innovation, demonstrating how collaboration accelerates innovation
“Australia’s Food and Beverage Accelerator is well positioned to bring together world-leading researchers from across universities to deliver new ingredients and premium products that consumers are increasingly demanding,” Dr Downs said.
“Co-investment across several universities and in partnership with industry allows us to join forces, build sovereign capability, create jobs for Australians and position our nation as a leader in the innovation of food and beverage products and related ingredients.”
Top image: From left, Eclipse Ingredients CEO Siobhan Coster and Dr James Behrendorff.
A simple improvement in oral care for hospitalised patients reduced the risk of non-ventilator hospital-acquired pneumonia by 60 percent, a trial of 8870 patients in three Australian hospitals has found.
The academic community of Australia has strengthened its presence in this year’s King’s Birthday 2026 Honours List in a powerful reminder of the impact of higher education on Australia’s future.